Lutetium oxodotreotide for the treatment of metastatic or inoperable gastroenteropancreatic neuroendocrine tumours (GEP-NETs): evidence synthesis to support a generic justification decision

Dullea A, Carrigan M, Harrington P, McGarry M, O’Brien K, O’Sullivan L, Ryan M, Spillane, S
Record ID 32018004905
Authors' objectives: 177Lu oxodotreotide is an established treatment in other countries. Topic exploration performed by HIQA in advance of developing this report indicated that a number of evidence syntheses have already been conducted in relation to its use for NETs. For these reasons, and in accordance with HIQA’s Methods for generic justification of new practices in ionising radiation, a ‘Review of prior evidence syntheses’ was undertaken. This review has three review questions (RQs) which focus on clinical effectiveness, quality of life, safety and adverse events. Reference is also made to the potential for public and occupational exposure to ionising radiation arising from the use of 177Lu oxodotreotide.
Project Status: Completed
Year Published: 2023
Requestor: HSE and the National Cancer Control Programme
English language abstract: An English language summary is available
Publication Type: Rapid Review
Country: Ireland
MeSH Terms
  • Neuroendocrine Tumors
  • Receptors, Peptide
  • Pancreatic Neoplasms
  • Carcinoma, Neuroendocrine
  • Lutetium
  • Intestinal Neoplasms
  • Radiopharmaceuticals
  • Lutetium
  • gastroenteropancreatic neuroendocrine tumours
  • 177 Lu
Organisation Name: Health Information and Quality Authority (HIQA)
Contact Address: Health Information and Quality Authority, George's Court, George's Lane,Smithfield, Dublin 7. PH : + 353 (01) 814 7464
Contact Name:
Contact Email:
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.